CAS No. |
84633-33-0 |
|---|---|
中文名称 |
(2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-二羟基-6-(羟甲基)-2-(((2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-四甲基二十二氢螺[萘并[2',1':4,5]茚并[2,1-b]呋喃-10,2'-吡喃]-4-基)氧基)四氢-2H-吡喃-3-基)氧基)-6-(羟甲基)四氢-2H-吡喃-3,4,5-三醇 |
英文名称 |
(2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(((2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-yl)oxy)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
别名 |
Asparanin A |
标准英文名 |
(2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(((2aR,4S,5'S,6aS,6bS,8aS,8bR,9S,10R,11aS,12aS,12bR)-5',6a,8a,9-tetramethyldocosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-yl)oxy)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
分子式 |
C39H64O13 |
分子量 |
740.93 |
精确分子量 |
740.43 |
SMILES |
C[C@H]1CC[C@@]2(OC1)O[C@H]1C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C |
标准SMILES |
C[C@@H]1CO[C@]2(CC1)O[C@H]1C[C@H]3[C@@H]4CC[C@@H]5C[C@H](CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]1[C@@H]2C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O |
用途 |
Asparanin A is an apoptosis inducer with anticancer activity; it inhibits cancer cell growth by inducing cell cycle arrest at the G0/G1 phase through the mitochondrial and PI3K/AKT signaling pathways; it also demonstrates in vivo efficacy by significantly suppressing tumor growth in a mouse xenograft model of Ishikawa endometrial cancer. |
InChIKey |
MMTWXUQMLQGAPC-XIBAMJMMSA-N |
|
|
评论 |
|---|